22 September 2017
Sign up for Norgine alerts
We are a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, we generated €368M total revenue and income.
We employ over 1,000 people across our commercial, development and manufacturing operations. We manage all aspects of product development, production, marketing, sales and supply.
Our approach and infrastructure is integrated and focused on ensuring that we win and deliver upon partnership opportunities for growth.
We are headquartered in the Netherlands and own an R&D site in Hengoed, Wales and two manufacturing sites, in Hengoed, Wales and in Dreux, France.
Overall, we have sites and offices in the UK (Harefield and Hengoed), France (Rueil and Dreux), Germany (Marburg), Belgium (Heverlee), The Netherlands (Amsterdam), Nordics (Copenhagen), Switzerland (Muttenz), Austria (Vienna), Italy (Milan), Portugal (Lisbon) and Spain (Madrid). Outside Europe, we have offices in Australia and New Zealand (Sydney).
We employ over 1,000 employees. We have demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access, sales and marketing expertise across Europe, Australia and New Zealand.
*total revenue and income consist of product sales, partnering milestones and other income
Down 2% from 2015 due to currency and disposals
Underlying growth up by 6.8%* driven by XIFAXAN®
Partnering is core to our business. Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We find and work with partners with complementary skills and a shared vision for improving healthcare and the lives of patients and their carers.